Hair Care Practices for Androgenic Alopecia

Alopecia can be divided into bidding in which the hair follicle is normal but the cycling of hair growth is abnormal and disorders in which the hair follicle is bedraggled. This is the most common cause of hair loss in women. Other common hair disorders include alopecia areata, telogen effluvium, cicatricial alopecia, and traumatic alopecias. The diagnosis is remarkably based on a thorough history and a focused physical examination. In many of the patients, selected laboratory tests or punch biopsy may be needed. Topically administrated minoxidil is labeled for the management of androgenetic alopecia in women.

There are three forms of alpha reductase receptor enzymes, and type I and type II are epoch-making in the handling of AGA. Type I is placed in the skin, considering the sebaceous glands and hair follicles, and type II is set in the inner root sheath of hair follicles in the scalp, face, chest, genitals, and prostatic gland. The hair-growth cycle is also smitten in AGA. Hair in the telogen, or dormant, phase is more overriding than hair in the anagen, or growth, stage. This leads to a lessening in hair on certain areas of the head. In addition, some of the hair follicles are smaller and highly sensitive to androgen. The pattern in which the hair loss occurs is uninhibitedly planned by the distribution of these smaller hair follicles.

Although alopecia can occur anywhere on the body, it is most distressing when it deteriorates the scalp. Hair loss can range from a small bare patch that is easily masked by hair styling to a more diffuse and obvious structure. Alopecia in women has been found to have importantly deleterious effects on self-esteem, psychological well-being, and body image.

Treatments for California androgenic alopecia:

A careful history often states the underlying cause of alopecia. Decisive factors include the duration and pattern of hair loss, whether the hair is damaged or shed at the roots, and whether shedding or thinning has enhanced. The patient’s diet, medics, present and past medical conditions, and family record of alopecia are other all-important factors.

If the diagnosis is not clear based on the history and physical scrutiny, selected science labs tests and, occasionally, punch biopsy may be pointed.

  1. Minoxidil (Rogaine)

The solution increases the length of time follicles spend in anagen, it “wakes up” follicles that are in catagen, and it elaborates the actual follicles. The mechanism by which minoxidil effects these changes is not noted till now. Vellus hairs enlarge and are regenerated to terminal hairs. In addition, shedding is attenuated. Commercial preparations comprise of minoxidil in a propylene glycol base. Allergic reactions to this base limit the usefulness of minoxidil therapy in some women for curing California androgenic alopecia.

  • Exogenous Estrogen

Exogenous estrogen is used less often now, because minoxidil is more effectual. In fertile women with androgenetic alopecia who ask for oral contraception, it is important to choose a pill containing the least androgenic progestogen.

  • Spironolactone (Aldactone)

This drug is a weak contending inhibitor of androgen binding to androgen receptors. It also folds down the synthesis of testosterone. For these reasons, orally administered spironolactone has been tried in the care of androgenetic alopecia, although questions remain about its utility. This drug can be beneficial in women who also have hirsuitism.

  • Finasteride (Proscar)

Finasteride should not be used for females of childbearing age, because 5α-reductase inhibitors may cause mental defectiveness of the external genitalia in the male fetus. Moreover, finasteride has not been shown to be useful in postmenopausal women with California androgenic alopecia

Thus, we conclude AGA is a genetically determined disorder defined by the gradual conversion of terminal hairs into open-ended, and finally into vellus, hairs. It is an highly common malady that affects men and women. Only two drugs presently have US Food and Drug Administration (FDA)–approved indications for handling California androgenic alopecia: minoxidil and finasteride.